Axa
ACLS icon

Axa’s Axcelis ACLS Stock Holding History

Axa’s Portfolio ACLS Stock Details ACLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,047
Closed -$2.46M – 1058
2024
Q1 		$2.46M Sell
22,047
-18,153
-45% -$2.16M 0.01% 723
2023
Q4 		$5.21M Sell
40,200
-20,100
-33% -$2.77M 0.02% 543
2023
Q3 		$9.83M Buy
60,300
+5,900
+11% +$1.04M 0.03% 397
2023
Q2 		$9.97M Sell
54,400
-3,700
-6% -$533K 0.03% 421
2023
Q1 		$7.74M Buy
58,100
+5,500
+10% +$646K 0.03% 464
2022
Q4 		$4.17M Buy
52,600
+400
+0.8% +$28.2K 0.02% 650
2022
Q3 		$3.16M Buy
+52,200
New +$3.37M 0.01% 671
2022
Q2 		– Sell
-13,300
Closed -$1M – 1107
2022
Q1 		$1M Sell
13,300
-43,500
-77% -$2.97M ﹤0.01% 954
2021
Q4 		$4.24M Buy
+56,800
New +$3.37M 0.01% 702
2018
Q1 		– Sell
-22,600
Closed -$649K – 1362
2017
Q4 		$649K Sell
22,600
-4,900
-18% -$154K ﹤0.01% 1101
2017
Q3 		$752K Buy
+27,500
New +$609K ﹤0.01% 1025

Other funds holding ACLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Axa's ACLS Position: Q2 2024 in Review

Axa sold out of Axcelis (ACLS) in Q2 2024, closing a stake of 22,047 shares — an estimated $2.46M sold.

Axa first reported a position in ACLS in Q3 2017 and held it in 11 quarters. The position peaked at $9.97M in Q2 2023. 392 funds tracked by Wall St. Rank hold ACLS as of Q2 2024.

  • Axa reported no remaining Axcelis position as of Q2 2024 after selling out during the quarter.
  • Axa sold 22,047 Axcelis shares in Q2 2024, an estimated $2.46M.
  • Axa first reported a position in Axcelis in Q3 2017 and held it in 11 quarters.
  • Axa's Axcelis position peaked at $9.97M in Q2 2023.
  • 392 funds tracked by Wall St. Rank held Axcelis as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.